These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease. Inam Z; Tisdale JF; Leonard A Expert Rev Hematol; 2023; 16(11):879-903. PubMed ID: 37800996 [TBL] [Abstract][Full Text] [Related]
5. Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies. Malhotra M; Shenoy S Transfus Apher Sci; 2022 Oct; 61(5):103554. PubMed ID: 36096996 [TBL] [Abstract][Full Text] [Related]
6. Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis. Aydin M; Dovern E; Leeflang MMG; de la Fuente J; Kassim AA; Biemond BJ; Nur E Transplant Cell Ther; 2021 Dec; 27(12):1004.e1-1004.e8. PubMed ID: 34537420 [TBL] [Abstract][Full Text] [Related]
7. Alternative donor allogeneic hematopoietic cell transplantation for hemoglobinopathies. Alfraih F; Aljurf M; Fitzhugh CD; Kassim AA Semin Hematol; 2016 Apr; 53(2):120-8. PubMed ID: 27000737 [TBL] [Abstract][Full Text] [Related]
8. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally. Kassim AA; DeBaun MR Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):532-541. PubMed ID: 38066894 [TBL] [Abstract][Full Text] [Related]
9. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314 [TBL] [Abstract][Full Text] [Related]
10. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! Kindwall-Keller TL; Ballen KK Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462 [TBL] [Abstract][Full Text] [Related]
11. Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy. Kassim AA; Leonard A J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013014 [TBL] [Abstract][Full Text] [Related]
12. Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease. Fitzhugh CD; Abraham A; Hsieh MM Adv Exp Med Biol; 2017; 1013():123-153. PubMed ID: 29127679 [TBL] [Abstract][Full Text] [Related]
13. Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease. Limerick E; Abraham A J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807140 [TBL] [Abstract][Full Text] [Related]
14. Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease. Marzollo A; Calore E; Tumino M; Pillon M; Gazzola MV; Destro R; Colombatti R; Marson P; Tison T; Colpo A; Mainardi C; Gabelli M; Boaro MP; Rossin S; Strano A; Quaglia N; Menzato F; Basso G; Sainati L; Messina C Mediterr J Hematol Infect Dis; 2017; 9(1):e2017014. PubMed ID: 28293402 [TBL] [Abstract][Full Text] [Related]
16. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? Leonard A; Tisdale J; Abraham A Br J Haematol; 2020 May; 189(3):408-423. PubMed ID: 32034776 [TBL] [Abstract][Full Text] [Related]
17. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor? Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure. Lawal RA; Walters MC; Fitzhugh CD Hematol Oncol Clin North Am; 2022 Dec; 36(6):1313-1335. PubMed ID: 36400545 [TBL] [Abstract][Full Text] [Related]
19. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564 [TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]